The ability of these compounds to disrupt the interaction between E6 and critical tumor suppressors, like TP-53 and pRb, could lead to the development of novel therapeutic protocols aimed at preventing or treating HPV-induced malignancies. This evidence concerns the gene TP53 and neoplasm.